MA-ELECTRA-VEHICLES
11.4.2022 08:02:11 CEST | Business Wire | Press release
On April 5, 2022, automotive industry leader Alexander (Alex) Hitzinger was appointed to the Board of Directors at Electra Vehicles, Inc. as an Independent Board Member. The appointment marks another critical milestone for the growing AI battery software startup as the company expands its expert roster of electric vehicle leaders from the transportation industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220410005015/en/
Hitzinger boasts an extensive engineering and leadership career where he led key autonomous and electric vehicle projects. His career began at Toyota as a development engineer before working in the Formula 1 world as Head of Formula 1 Development at Cosworth and Head of Advanced Technologies at Red Bull’s Formula 1 Team. His penchant for leading cutting edge automotive technology projects led him to serve as Technical Director for the three times victorious Porsche 919 at the 24 Hours of Le Mans and Head of Product Design at Apple for Project Titan before co-founding and serving as CEO at ARTEMIS, where he lead the creation of a visionary autonomous vehicle concept. Most recently, Hitzinger served as Senior Vice President of Autonomous Driving at VW Group and Member of the Executive Board VWN, where he was involved in the development of the ID Buzz. With more than 20 years of experience in the automotive and electric vehicle industries, Hitzinger begins a new phase of his career with the aim of supporting promising young companies with disruptive technologies as they enter the automotive and electric vehicle world stage.
“I am looking for outstanding companies, with industry leading technologies, where I can help the management in deriving a successful strategy for scaling the company and the technology. Electra Vehicles, Inc. is exactly this type of company,” says Hitzinger. “The electrification of transportation is in full swing, but in many areas of the technology stack, there are still outdated technologies deployed. Electra is closing one of these gaps with its sophisticated battery performance management, and therefore I couldn’t be happier about joining Electra’s Board of Directors.”
CEO and Co-founder of Electra Vehicles, Fabrizio Martini, expresses his delight at welcoming Hitzinger to the Board: “The Electra team is honored, proud, and glad to welcome on its Board of Directors an extraordinary visionary like Alex Hitzinger. Alex is a world-renowned expert and award-winning talent in the Mobility sector. His experience, knowledge, and vision will guide Electra Vehicles, Inc. to make a significant global impact. I am genuinely excited to start partnering with Alex to bring the most advanced ML/AI-based technology worldwide for battery management solutions in the marketplace to enhance today’s transition to electric transportation.”
About Electra Vehicles, Inc.
Electra Vehicles is a leading B2B AI software company headquartered in Boston, MA, USA with a presence in Italy that produces embedded and Cloud-connected software to optimize the performance of electric vehicle battery systems for range, lifetime, charging, and safety benefits. Electra’s onboard EVE-Ai™ 360 Adaptive Controls and Cloud-based EVE-Ai™ Fleet Analytics are software that provide battery system performance insights, battery-conscious driver recommendations, and intelligent charging control strategies based on a continuously updating Adaptive Cell Model, making Electra’s EVE-Ai™ a necessity for electrified applications worldwide. In 2021, Electra Vehicles, Inc. became a BlackBerry IVY Fund investee and is a proud member of the BlackBerry IVY ecosystem.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220410005015/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom